Literature DB >> 16931165

Tobacco habits modulate autosomal dominant nocturnal frontal lobe epilepsy.

Eylert Brodtkorb1, Fabienne Picard.   

Abstract

Mutations in neuronal nicotinic acetylcholine receptors have been demonstrated in autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). The beneficial effect of nicotine administration was previously reported in one single case. We investigated the influence of the tobacco habits of 22 subjects from two pedigrees with alpha4 mutations (776ins3 and S248F). Subjects were interviewed with respect to pattern of nicotine intake and seizures. Seizure freedom was significantly associated with tobacco use (P=0.024). All seven nonsmokers with manifest ADNFLE had persistent seizures. Seizure fluctuations, including long remissions, corresponded to changes in tobacco habits in several patients. One patient who recently had begun treatment with transdermal nicotine experienced improvement. We conclude that tobacco appears to be an environmental factor that influences seizure susceptibility in ADNFLE. Inactivation by desensitization of the mutant receptors by nicotine may explain the beneficial effect. The efficacy and safety of transdermal nicotine in ADNFLE should be further explored.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16931165     DOI: 10.1016/j.yebeh.2006.07.008

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  16 in total

Review 1.  Nocturnal frontal lobe epilepsy.

Authors:  Lino Nobili; Paola Proserpio; Romina Combi; Federica Provini; Giuseppe Plazzi; Francesca Bisulli; Laura Tassi; Paolo Tinuper
Journal:  Curr Neurol Neurosci Rep       Date:  2014-02       Impact factor: 5.081

2.  Pearls & Oysters: A case of refractory nocturnal seizures: Putting out fires without smoke.

Authors:  Pantelis P Pavlakis; Laurie M Douglass
Journal:  Neurology       Date:  2015-05-05       Impact factor: 9.910

3.  Nicotinic receptor abnormalities as a biomarker in idiopathic generalized epilepsy.

Authors:  Valentina Garibotto; Michael Wissmeyer; Zoi Giavri; Rachel Goldstein; Yann Seimbille; Margitta Seeck; Osman Ratib; Sven Haller; Fabienne Picard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-29       Impact factor: 9.236

4.  Epilepsy and tobacco smoking: a cross-sectional study.

Authors:  Omar Torriani; Frédéric Vuilleumier; Thomas Perneger; Paul-Andre Despland; Malin Maeder; Anne-Chantal Héritier-Barras; Serge Vulliemoz; Margitta Seeck; Andrea O Rossetti; Fabienne Picard
Journal:  J Neurol       Date:  2016-07-14       Impact factor: 4.849

Review 5.  Neural systems governed by nicotinic acetylcholine receptors: emerging hypotheses.

Authors:  Julie M Miwa; Robert Freedman; Henry A Lester
Journal:  Neuron       Date:  2011-04-14       Impact factor: 17.173

Review 6.  Therapy in Sleep-Related Hypermotor Epilepsy (SHE).

Authors:  Gian Maria Asioli; Simone Rossi; Francesca Bisulli; Laura Licchetta; Paolo Tinuper; Federica Provini
Journal:  Curr Treat Options Neurol       Date:  2020-01-30       Impact factor: 3.598

7.  Nicotine normalizes intracellular subunit stoichiometry of nicotinic receptors carrying mutations linked to autosomal dominant nocturnal frontal lobe epilepsy.

Authors:  Cagdas D Son; Fraser J Moss; Bruce N Cohen; Henry A Lester
Journal:  Mol Pharmacol       Date:  2009-02-23       Impact factor: 4.436

Review 8.  Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery.

Authors:  Henry A Lester; Cheng Xiao; Rahul Srinivasan; Cagdas D Son; Julie Miwa; Rigo Pantoja; Matthew R Banghart; Dennis A Dougherty; Alison M Goate; Jen C Wang
Journal:  AAPS J       Date:  2009-03-12       Impact factor: 4.009

9.  Distinctive effects of nicotinic receptor intracellular-loop mutations associated with nocturnal frontal lobe epilepsy.

Authors:  Maegan M Weltzin; Jon M Lindstrom; Ronald J Lukas; Paul Whiteaker
Journal:  Neuropharmacology       Date:  2015-11-10       Impact factor: 5.250

10.  Probing the non-canonical interface for agonist interaction with an α5 containing nicotinic acetylcholine receptor.

Authors:  Christopher B Marotta; Crystal N Dilworth; Henry A Lester; Dennis A Dougherty
Journal:  Neuropharmacology       Date:  2013-10-18       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.